7 results
Primary:to investigate the effects on heart rate (HR) and rhythm of concomitant administration of the study drug with a calcium-channel blocker (CCB) or a beta-blocker (BB)Secondary:- to investigate the effects on blood pressure (BP) of concomitant…
Primary:to evaluate the effects of a moderate CYP3A4/5 inhibitor, diltiazem on the pharmacokinetics and pharmacodynamics (Thrombin and TRAP-induced platelet aggregation) of the study drug and its known metabolitessecundary:to evaluate the effects of…
- To evaluate the pharmacokinetic (PK) profile of the combination of GLPG3067, GLPG2222, and GLPG2737 following repeated morning versus evening doses given to healthy female subjects - To evaluate the safety and tolerability of the combination of…
PRIMARY OBJECTIVESParts 1 & 2* To assess safety and tolerability of the combination of GLPG2451 and GLPG2222, with and without GLPG2737 in adult subjects with CF* To characterize the PK of GLPG2451 and GLPG2222, with and without GLPG2737 (…
This study will provide an estimate of basic PK parameters for guadecitabine, an assessment of the routes and rates of elimination of radioactivity, and identification of metabolites and metabolic pathways.
- To assess the relative bioavailability of GLPG2737 administered as a single capsule compared to a single oral suspension in the fed state.- To assess the safety and tolerability in healthy subjects of GLPG2737 administered as a capsule and as an…
Main objective- To characterize the effect of GLPG2737 on growth in total kidneyvolume (TKV) compared to placebo.- To evaluate the safety and tolerability of oral doses of GLPG2737compared to placebo.Secondary objectives: - To characterize the…